A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022)
Background: The REFLECT phase-III trial has demonstrated the efficacy of lenvatinib in improving the overall survival of advanced hepatocellular carcinoma (HCC) patients, comparable to sorafenib. The rapidly evolving landscape of hepatocellular carcinoma therapy presents new avenues for lenvatinib....
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1159286/full |
| _version_ | 1797804446751653888 |
|---|---|
| author | Cong-Cong Wang Cai-Yan Yu Jing Zhang Rui Wang Xiang-Shuo Kong |
| author_facet | Cong-Cong Wang Cai-Yan Yu Jing Zhang Rui Wang Xiang-Shuo Kong |
| author_sort | Cong-Cong Wang |
| collection | DOAJ |
| description | Background: The REFLECT phase-III trial has demonstrated the efficacy of lenvatinib in improving the overall survival of advanced hepatocellular carcinoma (HCC) patients, comparable to sorafenib. The rapidly evolving landscape of hepatocellular carcinoma therapy presents new avenues for lenvatinib. This study aims to provide a scientometric analysis of publications and predict research hotspots in this field.Methods: Relevant publications were sourced from the Web of Science Core Collection (WoSCC) database up until November 2022. The bibliometrix tool in R was employed for scientometric analysis and visualization.Results: A total of 879 publications from 2014 to 2022 were obtained from WoSCC that met the established criteria. These studies involved 4,675 researchers from 40 countries, with an average annual growth rate of 102.5%. The highest number of publications was from Japan, followed by China, Italy, and the United States. The largest proportion of studies, 14.0% (n = 123), was contributed by FUDAN UNIV. The studies were published in 274 journals, with CANCERS (n = 53) being the top journal, followed by FRONTIERS IN ONCOLOGY (n = 51) and HEPATOLOGY RESEARCH (n = 36). The top ten journals accounted for 31.5% of the 879 studies. The most prolific authors were Kudo M (n = 51), Hiraoka A (n = 43), and Tsuji K (n = 38). A total of 1,333 keywords were analyzed, with the present research hotspots being “immune checkpoint inhibitors,” “prognosis,” and “pd-1.” Co-occurrence clustering analysis revealed the top keywords, authors, publications, and journals. Strong collaboration was identified in the field.Conclusion: This scientometric and visual analysis provides a comprehensive summary of the published articles on lenvatinib in HCC during 2014–2022, highlighting the research hotspots, knowledge domain, and frontiers. The results can provide insights into future research directions in this field. |
| first_indexed | 2024-03-13T05:37:18Z |
| format | Article |
| id | doaj.art-29b98a75b0b242b6817c6453f1e9dc79 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-13T05:37:18Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-29b98a75b0b242b6817c6453f1e9dc792023-06-14T05:35:44ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-06-011410.3389/fphar.2023.11592861159286A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022)Cong-Cong Wang0Cai-Yan Yu1Jing Zhang2Rui Wang3Xiang-Shuo Kong4Department of Oncology, Yantai Yuhuangding Hospital, Yantai, ChinaDepartment of Oncology, Yantai Yuhuangding Hospital, Yantai, ChinaSchool of Medicine, Huanghuai University, Zhumadian, Henan, ChinaDepartment of Respiratory Oncology, Fushan District People’s Hospital, Yantai, ChinaDepartment of Oncology, Yantai Yuhuangding Hospital, Yantai, ChinaBackground: The REFLECT phase-III trial has demonstrated the efficacy of lenvatinib in improving the overall survival of advanced hepatocellular carcinoma (HCC) patients, comparable to sorafenib. The rapidly evolving landscape of hepatocellular carcinoma therapy presents new avenues for lenvatinib. This study aims to provide a scientometric analysis of publications and predict research hotspots in this field.Methods: Relevant publications were sourced from the Web of Science Core Collection (WoSCC) database up until November 2022. The bibliometrix tool in R was employed for scientometric analysis and visualization.Results: A total of 879 publications from 2014 to 2022 were obtained from WoSCC that met the established criteria. These studies involved 4,675 researchers from 40 countries, with an average annual growth rate of 102.5%. The highest number of publications was from Japan, followed by China, Italy, and the United States. The largest proportion of studies, 14.0% (n = 123), was contributed by FUDAN UNIV. The studies were published in 274 journals, with CANCERS (n = 53) being the top journal, followed by FRONTIERS IN ONCOLOGY (n = 51) and HEPATOLOGY RESEARCH (n = 36). The top ten journals accounted for 31.5% of the 879 studies. The most prolific authors were Kudo M (n = 51), Hiraoka A (n = 43), and Tsuji K (n = 38). A total of 1,333 keywords were analyzed, with the present research hotspots being “immune checkpoint inhibitors,” “prognosis,” and “pd-1.” Co-occurrence clustering analysis revealed the top keywords, authors, publications, and journals. Strong collaboration was identified in the field.Conclusion: This scientometric and visual analysis provides a comprehensive summary of the published articles on lenvatinib in HCC during 2014–2022, highlighting the research hotspots, knowledge domain, and frontiers. The results can provide insights into future research directions in this field.https://www.frontiersin.org/articles/10.3389/fphar.2023.1159286/fullbibliometriclenvatinibhepatocellular carcinomaprognosisimmunotherapy |
| spellingShingle | Cong-Cong Wang Cai-Yan Yu Jing Zhang Rui Wang Xiang-Shuo Kong A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022) Frontiers in Pharmacology bibliometric lenvatinib hepatocellular carcinoma prognosis immunotherapy |
| title | A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022) |
| title_full | A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022) |
| title_fullStr | A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022) |
| title_full_unstemmed | A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022) |
| title_short | A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022) |
| title_sort | bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma 2014 2022 |
| topic | bibliometric lenvatinib hepatocellular carcinoma prognosis immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1159286/full |
| work_keys_str_mv | AT congcongwang abibliometricstudyontheutilizationoflenvatinibinhepatocellularcarcinoma20142022 AT caiyanyu abibliometricstudyontheutilizationoflenvatinibinhepatocellularcarcinoma20142022 AT jingzhang abibliometricstudyontheutilizationoflenvatinibinhepatocellularcarcinoma20142022 AT ruiwang abibliometricstudyontheutilizationoflenvatinibinhepatocellularcarcinoma20142022 AT xiangshuokong abibliometricstudyontheutilizationoflenvatinibinhepatocellularcarcinoma20142022 AT congcongwang bibliometricstudyontheutilizationoflenvatinibinhepatocellularcarcinoma20142022 AT caiyanyu bibliometricstudyontheutilizationoflenvatinibinhepatocellularcarcinoma20142022 AT jingzhang bibliometricstudyontheutilizationoflenvatinibinhepatocellularcarcinoma20142022 AT ruiwang bibliometricstudyontheutilizationoflenvatinibinhepatocellularcarcinoma20142022 AT xiangshuokong bibliometricstudyontheutilizationoflenvatinibinhepatocellularcarcinoma20142022 |